Cart
sales@molnova.com
NIBR-3049
CAS No. 1260181-14-3
NIBR-3049( TCS-21311 )
Catalog No. M11072 CAS No. 1260181-14-3
NIBR-3049 (TCS-21311) is a potent, highly selective JAK3 inhibitor with IC50 of 8 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNIBR-3049
-
NoteResearch use only, not for human use.
-
Brief DescriptionNIBR-3049 (TCS-21311) is a potent, highly selective JAK3 inhibitor with IC50 of 8 nM.
-
DescriptionNIBR-3049 (TCS-21311) is a potent, highly selective JAK3 inhibitor with IC50 of 8 nM, displays >100-fold selectivity over JAK1, JAK2 and TYK2, also inhibits PKCα, PKCθ, and GSK3β with IC50 of 13, 68, and 3 nM, respectively.
-
In VitroTCS 21311 (NIBR3049) exhibits IC50 values of 1.017, 2.550 and 8.055 μM for JAK1, JAK2 and TYK2, respectively?in a enzymatic Jak assay.TCS 21311 (NIBR3049) shows moderate activity in this cellular assay (IC50=689 nM, Jurkat cells), which is in good agreement with its enzymatic Pkc activity.
-
In Vivo——
-
SynonymsTCS-21311
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1260181-14-3
-
Formula Weight526.51
-
Molecular FormulaC27H25F3N4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (189.93 mM)
-
SMILESO=C(C(C1=CC(N2CCN(C(C(C)(O)C)=O)CC2)=CC=C1C(F)(F)F)=C3C4=CNC5=C4C=CC=C5)NC3=O
-
Chemical Name3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Thoma G, et al. J Med Chem. 2011 Jan 13;54(1):284-8.
molnova catalog
related products
-
AZD 4205
AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively.
-
Tofacitinib
Tofacitinib (CP-690550) is a potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays; displays 20- to 100-fold less potency for JAK2 and JAK1 (IC50=20 nM and 112 nM, respectively).
-
Lorpucitinib
Lorpucitinib (JNJ-64251330) is an orally available, selective and potent JAK kinase inhibitor for the study of inflammatory and gastrointestinal disorders associated with Janus kinase (JAK) signaling.
